AstraZeneca to set up division for vaccines and antibody therapies | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
July 24, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, JULY 24, 2025
AstraZeneca to set up division for vaccines and antibody therapies

Coronavirus chronicle

Reuters
10 November, 2021, 09:50 am
Last modified: 10 November, 2021, 09:55 am

Related News

  • Bangladesh vaccinates over 7.1m girls in programme combatting cervical cancer: Unicef
  • US Health Secretary Kennedy guts vaccine advisory committee
  • Govt plans to relocate country's first vaccine plant from Gopalganj to Munshiganj
  • Umrah pilgrims struggle with abrupt meningitis vaccination requirement amid shortage
  • Vaccination, early screening can prevent cervical cancer death for women

AstraZeneca to set up division for vaccines and antibody therapies

The company's Covid-19 shot is the biggest contributor to the COVAX vaccine sharing scheme backed by the WHO

Reuters
10 November, 2021, 09:50 am
Last modified: 10 November, 2021, 09:55 am
A vial of the AstraZeneca vaccine for the coronavirus disease (Covid-19) at one of the Youth centres where citizens can get the vaccines without prior registration, in an effort to boost the country's vaccination drive, in Cairo, Egypt, September 27, 2021. Photo :Reuters
A vial of the AstraZeneca vaccine for the coronavirus disease (Covid-19) at one of the Youth centres where citizens can get the vaccines without prior registration, in an effort to boost the country's vaccination drive, in Cairo, Egypt, September 27, 2021. Photo :Reuters

* News comes after review of vaccine operations

* Covid-19 shot has suffered setbacks during pandemic

* Company has antibody therapy proven to prevent infection

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

* Move shows company sees future for Covid-19 vaccine beyond pandemic


AstraZeneca is creating a separate division for vaccines and antibody therapies, the drugmaker said on Tuesday, to focus on its Covid-19 shot and coronavirus treatments after a series of setbacks during the pandemic.

Reuters reported in July that the Anglo-Swedish company was exploring options https://reut.rs/3bTjnX5 for its vaccine business and expected to have greater clarity on the matter by the end of 2021.

The new division, which will be led by executive vice-president of Europe and Canada, Iskra Reic, will combine research and development, manufacturing, as well as commercial and medical teams, a company spokesperson said.

"The team will be dedicated to our Covid-19 vaccine, our long-acting antibody combination and our developmental vaccine addressing multiple variants of concern, as well as to our existing portfolio for respiratory viral disease," the representative said.

The decision to set up a new business comes after a tumultuous 18 months for the drugmaker, which developed its Covid-19 vaccine in conjunction with the University of Oxford.

Production problems forced the company to cut deliveries to the European Union this year, prompting the bloc to launch a legal challenge that has now been settled.

Governments have also restricted its use among certain age groups due to links to rare blood clots. Regulators including the World Health Organization (WHO) have said, however, that the vaccine's overall benefits outweigh any risks.

AstraZeneca's application for US approval of its shot is taking longer than expected too.

But positive results from trials of its antibody cocktail as a preventative shot against Covid-19 have given AstraZeneca a major boost, potentially positioning it as a supplier of both Covid-19 vaccines and treatments. The antibody treatment is currently under review by European regulators.

BROADER MARKET?

The creation of the vaccines division, first reported by the Financial Times, indicates AstraZeneca sees a future for its Covid-19 shot beyond the pandemic but shouldn't be taken as a sign it is planning a full-scale entry into the broader vaccine market, Hargreaves Lansdown analyst Nicholas Hyett said.

"That would require significant new research and development investment, and as yet we have no indication that this is forthcoming," he said.

AstraZeneca has pledged to supply vaccines at cost during the pandemic. The not-for-profit strategy and challenges with the shot had fuelled speculation about whether it would want to keep the business in the long term.

The company's Covid-19 shot is the biggest contributor to the COVAX vaccine sharing scheme backed by the WHO.

"Vaccines is not a traditional area of strength (for AstraZeneca) ... but the new group structure suggests the company is looking to pull together certain operations across its portfolio to ensure they operate more effectively and more profitably," AJ Bell investment director Russ Mould said.

While AstraZeneca's Covid-19 vaccine remained a drag on profits in the second quarter, sales of the shot more than tripled to $894 million from the first three months of the year, making it one of the drugmaker's best-selling products.

AstraZeneca is due to report third-quarter results on Friday.

Top News / World+Biz

AstraZeneca / Vaccine / antibody

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • A file photo of former prime minister Sheikh Hasina. Photo: Collected
    Al Jazeera probe: Hasina, in call with Taposh, talks using helicopter to shoot, crush protesters in July uprising
  • Representational image. Photo: Collected
    Tariff issue: Bangladesh, US set for crucial virtual meeting on 29 July - not tommorow
  • News of The Day, 24 JULY 2025
    News of The Day, 24 JULY 2025

MOST VIEWED

  • Photo: Collected
    Bangladeshi man jailed for life in UK for murdering wife in front of their baby
  • Ctg port authority halts contractor recruitment for Kamalapur ICD operations for two months
    Ctg port authority halts contractor recruitment for Kamalapur ICD operations for two months
  • Fire at Cosmo School in Mirpur on 23 July 2025. Photo: TBS
    Fire breaks out at Cosmo School in Mirpur following generator explosion
  • Representational image. File Photo: Rajib Dhar/TBS
    Debate arises as edu adviser says postponed HSC exams of 22 and 24 July will be held on same day
  • BB issues dress code for all, discourages short-sleeved or length dresses, leggings for female staff
    BB issues dress code for all, discourages short-sleeved or length dresses, leggings for female staff
  • Infographics: TBS
    Stay orders won’t shield defaulters: BB governor 

Related News

  • Bangladesh vaccinates over 7.1m girls in programme combatting cervical cancer: Unicef
  • US Health Secretary Kennedy guts vaccine advisory committee
  • Govt plans to relocate country's first vaccine plant from Gopalganj to Munshiganj
  • Umrah pilgrims struggle with abrupt meningitis vaccination requirement amid shortage
  • Vaccination, early screening can prevent cervical cancer death for women

Features

Photo: Collected

24 July: More than 1400 arrested, 3 missing coordinators found

19h | Panorama
Photo: Mehedi Hasan/TBS

Aggrieved nation left with questions as citizens rally to help at burn institute

2d | Panorama
Photo: Mehedi Hasan/TBS

Mourning turns into outrage as Milestone students seek truth and justice

1d | Panorama
Illustration: TBS

Uttara, Jatrabari, Savar and more: The killing fields that ran red with July martyrs’ blood

2d | Panorama

More Videos from TBS

AI is uncovering the lost history of ancient Rome

AI is uncovering the lost history of ancient Rome

40m | Others
Jamaat Ameer's statement misleading: Chatra Dal general secretary

Jamaat Ameer's statement misleading: Chatra Dal general secretary

1h | TBS Today
Dollar gets upward push as BB buys $10m more in auction at even higher rate

Dollar gets upward push as BB buys $10m more in auction at even higher rate

2h | TBS Insight
Why is Korniya called the Jamdani Sari girl?

Why is Korniya called the Jamdani Sari girl?

1h | TBS Programs
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net